Taipei, Taiwan, October 18, 2016 – DKSH’s Business Unit Healthcare, the leading Market Expansion Services provider for healthcare companies seeking to grow their business in Asia, is the first company in Taiwan that has successfully passed Taiwan FDA's stricter audit standards. The GDP certification follows the Pharmaceutical Inspection Convention Co-operation Scheme (PIC/S) and underlines DKSH’s commitment to quality throughout the entire distribution process.
Since becoming a member of the PIC/S in 2013, the Taiwanese FDA has increased its focus of the regulation and auditing of the pharmaceutical healthcare market. To align with international standards, Taiwan’s FDA recently adjusted local GDP regulations and updated the standards of distribution services. DKSH Taiwan passed the GDP audit of the World Health Organization (WHO) as early as 2009.
Thomas Delemazure, General Manager, Business Unit Healthcare, DKSH Taiwan stated: “Our solid, capillary distribution and logistics platform is the backbone behind our portfolio of Market Expansion Services. We are pleased that our unwavering commitment to quality is recognized by local authorities. DKSH’s operations align with the strictest international quality and compliance standards. We remain committed to bringing the best services to our clients and customers.”
DKSH is the leading Market Expansion Services provider with a focus on Asia. As the term "Market Expansion Services" suggests, DKSH helps other companies and brands to grow their business in new or existing markets. Publicly listed on the SIX Swiss Exchange since 2012, DKSH is a global company headquartered in Zurich. With 770 business locations in 36 countries – 740 of them in Asia – and 28,300 specialized staff, DKSH generated net sales of CHF 10.1 billion in 2015. DKSH was founded in 1865. With strong Swiss heritage, the company has a long tradition of doing business in and with Asia and is deeply rooted in communities and businesses across Asia Pacific.
DKSH Business Unit Healthcare is the leading Market Expansion Services provider for healthcare companies seeking to grow their business in Asia. Custom-made offerings comprise registration, regulatory services, market entry studies, importation, customs clearance, marketing and sales, capillary physical distribution, invoicing and cash collection. Products available through DKSH Healthcare include pharmaceuticals, consumer health and over-the-counter (OTC) products, as well as medical devices. With 140 business locations in 13 countries and around 9,590 specialized staff, Business Unit Healthcare serves over 150,000 customers and generated net sales of CHF 5.0 billion in 2015.